Navigation Links
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
Date:11/1/2011

NEW YORK, Nov. 1, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease, today announced that a conference call will be held on Thursday, November 3, 2011 at 8:30 a.m. EDT to discuss results for the third quarter ended September 30, 2011 and a business outlook for the remainder of 2011. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SP
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014  Express Scripts (NASDAQ: ... nationally available 2015 Express Scripts Medicare ® Prescription ... network featuring Walgreens (NYSE: WAG ) (NASDAQ: ... value, choice and clinical support  for their Medicare dollars. ... Scripts Medicare Value or Choice ...
(Date:10/1/2014)... Oct. 1, 2014 Ardelyx, Inc. ... biopharmaceutical company focused on cardio-renal, gastrointestinal and ... its 371 patient Phase 2b clinical trial ... bowel syndrome (IBS-C).  Results from this study ... in IBS-C symptoms for tenapanor-treated patients compared ...
(Date:9/30/2014)... the health and safety of Canadians is our government,s highest priority.  ... tools at its disposal to help ensure that the drugs Canadians ... that end, Health Canada has taken ... of all drug products from three plants in ... Apotex Pharmachem India Pvt Ltd , Apotex Research Private Limited ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6Statement by the Honourable Rona Ambrose on the import ban of drug products from three plants in India 2
... 2011 Reportlinker.com announces that a new market ... Hospital Mammography Census ... the most comprehensive European market report on the ... Mammography, R&F, Angiography, CT, MRI,) and radiology IT ...
... 20, 2011 Perrigo Company (Nasdaq: PRGO; TASE) today ... acquire substantially all of the assets of Paddock Laboratories, ... generic pharmaceutical products for approximately $540 million in cash. ... a result of the acquisition of Paddock,s assets. The ...
Cached Medicine Technology:Reportlinker Adds Hospital Mammography Census 2Perrigo to Acquire Assets of Paddock Labs for $540 Million 2Perrigo to Acquire Assets of Paddock Labs for $540 Million 3Perrigo to Acquire Assets of Paddock Labs for $540 Million 4Perrigo to Acquire Assets of Paddock Labs for $540 Million 5
(Date:10/1/2014)... (PRWEB) October 01, 2014 Join the more ... Eating Disorder Treatment Center’s first ever charity golf tournament to ... people with eating disorders who cannot afford treatment. The tournament ... Club in Eureka, Mo. , The day-long event starts ... A reception and award dinner will begin at 5 p.m. ...
(Date:10/1/2014)... Beverly Hills, California (PRWEB) October 01, 2014 ... relationship expert, Dr. Kathleen Mojas is celebrating 20 years ... she has assisted hundreds of people to achieve greater ... released an important list of warning signs and suggestions ... relationship. , Dr. Mojas explains: “Believe it or ...
(Date:10/1/2014)... Innovations announces the upcoming airing of ... Monday, October 20, 2014 at 7:30 a.m. EST/PT via ... behind the scenes to learn about Break the Cycle’s ... the practical help and information Break the Cycle provides ... signs of abuse, how to navigate the legal system, ...
(Date:10/1/2014)... October 01, 2014 NoteSwift Inc., announced ... versions 10.0, 12.1 and 13.0. NoteSwift is the bridge ... commands to navigate and document clinical information at the ... spends creating a patient note by more than half ... the major pain points providers state impedes EHR use ...
(Date:10/1/2014)... 01, 2014 Scientists at the University ... that target immune system proteins has the power to ... posted details of the new study on their website. ... , Researchers in the UWA School of Pathology and ... to mice with mesothelioma with promising results. , ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... software medication solution reduces complexity in, patient-specific medication ... ... LAS VEGAS, ASHP, Dec. 3 Ushering in ... OMCL ) a leading provider,of system solutions ...
... with Centers of Influence, POWAY, Calif., Dec. ... leading provider of medical diagnostic imaging systems,and services ... the signing of a letter of agreement with ... of the agreement, the fifth since the inception ...
... advertisements are appearing on television, the bulk of ... spend annually to market their products is targeted ... students. , A literature review by researchers ... the Regenstrief Institute, Inc. published in the December ...
... , , MONDAY, Dec. 3 (HealthDay News) -- Avandia, a ... bone loss, according to a new study conducted in mice. ... may speed osteoporosis, the thinning of the bones that can ... appear in the Dec. 2 online issue of Nature ...
... ANGELES, Dec. 2 Hurricane Katrina was one ... and was the costliest (at an,estimated $86 billion.) ... in the aftermath. Witnessing the,destruction/displacement from the West ... to take his new school training techniques, with,old ...
... Everything from Christmas trees to fake snow can trigger symptoms, ... It,s easy for the holidays to become the season ... or other allergies and asthma, say experts at the American ... preventive measures can cut symptoms to a minimum, they say. ...
Cached Medicine News:Health News:Omnicell Debuts Industry's First Total Automated Patient-Specific Management Solution 2Health News:Omnicell Debuts Industry's First Total Automated Patient-Specific Management Solution 3Health News:Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement 2Health News:Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement 3Health News:Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement 4Health News:Do medical schools affect the way future doctors interact with drug companies? 2Health News:Diabetes Drug Avandia Could Weaken Bones 2Health News:CJ Transforms His Functional Fitness Program Into an Additional Resource for the Hurricane Katrina Survivors 2Health News:CJ Transforms His Functional Fitness Program Into an Additional Resource for the Hurricane Katrina Survivors 3Health News:'Tis the Season For Allergy, Asthma 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Adjustable speed vortex with inter-changeable heads , 110 V...
Inquire...
Adjustable speed vortex with inter-changeable heads, 110 V...
Medicine Products: